Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C

被引:42
作者
Wu, J
Chen, S [1 ]
Gui-Qiang, W
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Infect Dis, Harbin 150086, Peoples R China
[2] PeiKing Univ, Hosp 1, Dept Infect Dis, PeiKing, Peoples R China
关键词
fatty liver; genotype; hepatitis C; insulin; sustained virologic response;
D O I
10.1111/j.1478-3231.2006.01219.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: Hepatic steatosis is a histological feature in patients with chronic hepatitis C (CHC) and adversely affects the virologic response rates to anti-hepatitis C virus (HCV) therapy. The aim of this study is to investigate whether the fatty liver and related factors have impact on the efficacy in CHC treated with peginterferon and ribavirin, and the associations between HCV genotyping and fatty liver. Methods: Ninety-eight patients received subcutaneously 180 mu g peginterferon alpha-2a once a week plus ribavirin. HCV genotypes and the levels of plasma insulin of patients were measured. Fatty liver was detected by B ultrasound. The body mass index (BMI), waist-to-hip ratio (WHR) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated. Results: Among 98 CHC patients, 38 (38.8%) were infected with genotype 1; 44 (44.9%) with genotype 2; 13 (13.3%) with genotype 3; 3 (3.0%) with indeterminate genotype. The prevalence of fatty liver was 10.5%, 11.4%, 38.5% in patients infected with HCV genotype 1, 2, 3, respectively, which suggested that the distribution of fatty liver in different HCV genotypes was imbalanced (chi(2)=6.758, P=0.034). In univariate analysis, the efficacy of combination therapy was significantly associated with BMI (P=0.011), WHR (P=0.024), the levels of plasma insulin (P=0.001), genotype (P=0.036), presence of fatty liver (P=0.028), treatment dosage and duration (P=0.012) and HOMA-IR (P=0.002). With binary logistic regression analysis, the plasma insulin levels and HOMA-IR showed independent predictors to the efficacy of antiviral therapy. Conclusion: The prevalence of fatty liver in HCV genotype 3 was markedly higher than that of other genotypes. The BMI, WHR, the levels of plasma insulin, genotype, presence of fatty liver, treatment dosage and duration and HOMA-IR were associated with the sustained virologic response. The level of plasma insulin and HOMA-IR were independent factors for predicting effect of antiviral therapy.
引用
收藏
页码:166 / 172
页数:7
相关论文
共 33 条
[1]   Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity [J].
Adinolfi, LE ;
Gambardella, M ;
Andreana, A ;
Tripodi, MF ;
Utili, R ;
Ruggiero, G .
HEPATOLOGY, 2001, 33 (06) :1358-1364
[3]  
Bell AC, 2002, AM J EPIDEMIOL, V155, P346, DOI 10.1093/aje/155.4.346
[4]  
BIDCEGLIE DAM, 2002, HEPATOLOGY, V36, pS121
[5]   High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C [J].
Bressler, BL ;
Guindi, M ;
Tomlinson, G ;
Heathcote, J .
HEPATOLOGY, 2003, 38 (03) :639-644
[6]   Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies [J].
Castéra, L ;
Hézode, C ;
Roudot-Thoraval, F ;
Bastie, A ;
Zafrani, ES ;
Pawlotsky, JM ;
Dhumeaux, D .
GUT, 2003, 52 (02) :288-292
[7]   NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome [J].
Chitturi, S ;
Abeygunasekera, S ;
Farrell, GC ;
Holmes-Walker, J ;
Hui, JM ;
Fung, C ;
Karim, R ;
Lin, R ;
Samarasinghe, D ;
Liddle, C ;
Weltman, M ;
George, J .
HEPATOLOGY, 2002, 35 (02) :373-379
[8]   SURVEY OF MAJOR GENOTYPES AND SUBTYPES OF HEPATITIS-C VIRUS USING RFLP OF SEQUENCES AMPLIFIED FROM THE 5' NONCODING REGION [J].
DAVIDSON, F ;
SIMMONDS, P ;
FERGUSON, JC ;
JARVIS, LM ;
DOW, BC ;
FOLLETT, EAC ;
SEED, CRG ;
KRUSIUS, T ;
LIN, C ;
MEDGYESI, GA ;
KIYOKAWA, H ;
OLIM, G ;
DURAISAMY, G ;
CUYPERS, T ;
SAEED, AA ;
TEO, D ;
CONRADIE, J ;
KEW, MC ;
LIN, M ;
NUCHAPRAYOON, C ;
NDIMBIE, OK ;
YAP, PL .
JOURNAL OF GENERAL VIROLOGY, 1995, 76 :1197-1204
[9]   Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? [J].
Day, CP .
GUT, 2002, 50 (05) :585-588
[10]   Steatohepatitis: A tale of two "hits"? [J].
Day, CP ;
James, OFW .
GASTROENTEROLOGY, 1998, 114 (04) :842-845